Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept....
SHANGHAI, April 9, 2025 /PRNewswire/ -- JOY GROUP (Shanghai Juyi Cosmetics Co., Ltd.) has announced its financial results for the 2024 fiscal year, achieving...